BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 29524828)

  • 1. Inhibition of pMAPK14 Overcomes Resistance to Sorafenib in Hepatoma Cells with Hepatitis B Virus.
    Witt-Kehati D; Fridkin A; Alaluf MB; Zemel R; Shlomai A
    Transl Oncol; 2018 Apr; 11(2):511-517. PubMed ID: 29524828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
    Kim JS; Choi GH; Jung Y; Kim KM; Jang SJ; Yu ES; Lee HC
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1487-1501. PubMed ID: 29858683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib.
    Mao K; Zhang J; He C; Xu K; Liu J; Sun J; Wu G; Tan C; Zeng Y; Wang J; Xiao Z
    Cancer Lett; 2014 Oct; 352(2):245-52. PubMed ID: 25034398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
    Saidak Z; Giacobbi AS; Louandre C; Sauzay C; Mammeri Y; Galmiche A
    Cancer Lett; 2017 Apr; 392():1-8. PubMed ID: 28161506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
    Chen Y; Liu YC; Sung YC; Ramjiawan RR; Lin TT; Chang CC; Jeng KS; Chang CF; Liu CH; Gao DY; Hsu FF; Duyverman AM; Kitahara S; Huang P; Dima S; Popescu I; Flaherty KT; Zhu AX; Bardeesy N; Jain RK; Benes CH; Duda DG
    Sci Rep; 2017 Mar; 7():44123. PubMed ID: 28276530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression.
    Kim HY; Jung HU; Yoo SH; Yoo KS; Cheong J; Park BS; Yun I; Yoo YH
    Cancer Lett; 2014 Dec; 355(1):61-9. PubMed ID: 25218348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence.
    Huang P; Zhuang B; Zhang H; Yan H; Xiao Z; Li W; Zhang J; Tang Q; Hu K; Koeffler HP; Wang J; Yin D
    Clin Cancer Res; 2015 Oct; 21(19):4420-30. PubMed ID: 26059188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
    J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brassicasterol inhibits hepatitis B virus-associated hepatocellular carcinoma development via suppression of AKT signaling pathway.
    Zeng J; Wu J; Pang S; Wang F; Yu X; Zhang S; Zeng J; Yan J; Lian J
    Infect Agent Cancer; 2023 Apr; 18(1):22. PubMed ID: 37081537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canonical WNT Signaling Activated by WNT7B Contributes to L-HBs-Mediated Sorafenib Resistance in Hepatocellular Carcinoma by Inhibiting Mitophagy.
    Liu LJ; Lv Z; Xue X; Xing ZY; Zhu F
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus promotes β-catenin-signalling and disassembly of adherens junctions in a Src kinase dependent fashion.
    von Olshausen G; Quasdorff M; Bester R; Arzberger S; Ko C; van de Klundert M; Zhang K; Odenthal M; Ringelhan M; Niessen CM; Protzer U
    Oncotarget; 2018 Sep; 9(74):33947-33960. PubMed ID: 30338037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma.
    Xia L; Huang W; Tian D; Zhu H; Zhang Y; Hu H; Fan D; Nie Y; Wu K
    J Hepatol; 2012 Sep; 57(3):600-12. PubMed ID: 22613004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
    Dietrich P; Koch A; Fritz V; Hartmann A; Bosserhoff AK; Hellerbrand C
    Gut; 2018 Jul; 67(7):1328-1341. PubMed ID: 29275358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
    Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
    Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein.
    Zhang S; Gao S; Zhao M; Liu Y; Bu Y; Jiang Q; Zhao Q; Ye L; Zhang X
    Cancer Lett; 2017 Apr; 392():94-104. PubMed ID: 28192212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression.
    Zhang S; Li N; Sheng Y; Chen W; Ma Q; Yu X; Lian J; Zeng J; Yang Y; Yan J
    Infect Agent Cancer; 2021 Mar; 16(1):20. PubMed ID: 33757557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus X protein promotes interleukin-7 receptor expression via NF-κB and Notch1 pathway to facilitate proliferation and migration of hepatitis B virus-related hepatoma cells.
    Kong F; Hu W; Zhou K; Wei X; Kou Y; You H; Zheng K; Tang R
    J Exp Clin Cancer Res; 2016 Nov; 35(1):172. PubMed ID: 27821177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.